• TAVR safe in low-surgical-risk patients

    The Low-Risk TAVR trial, the first of its kind, sends “a strong signal” that it is safe to expand transcatheter aortic valve replacement (TAVR) to patients with symptomatic severe aortic stenosis who are at low risk for surgical mortality.

    Top-line results from LRT showed zero all-cause mortality and zero disabling stroke at 30 days in 200 low-risk patients who underwent TAVR.

    Watch Drs. Satler and Waksman discuss the results on CardioTube.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details